

L21 ANSWER 4 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN  
 ACCESSION NUMBER: 2002:921893 CAPLUS  
 DOCUMENT NUMBER: 137:389223  
 TITLE: Benzimidazole proton pump inhibitor dosage forms  
 INVENTOR(S): Phillips, Jeffrey Owen  
 PATENT ASSIGNEE(S): The Curators of the University of Missouri, USA  
 SOURCE: U.S., 31 pp., Cont.-in-part of U.S. Ser. No. 183,422,  
 abandoned.  
 CODEN: USXXAM  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 5  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6489346	B1	20021203	US 2000-481207	20000111
US 5840737	A	19981124	US 1996-680376	19960715
WO 2001051050	A1	20010719	WO 2001-US796	20010110
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1246622	A1	20021009	EP 2001-904818	20010110
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001007565	A	20030211	BR 2001-7565	20010110
JP 2003519656	T2	20030624	JP 2001-551474	20010110
US 2002045646	A1	20020418	US 2001-901942	20010709
US 2003118669	A1	20030626	US 2002-68437	20020205
NO 2002003313	A	20020830	NO 2002-3313	20020709
US 2003144306	A1	20030731	US 2002-260132	20020930
PRIORITY APPLN. INFO.:				
US 1996-9608P P 19960104				
US 1996-680376 A2 19960715				
US 1998-183422 B2 19981030				
US 2000-481207 A 20000111				
WO 2001-US796 W 20010110				

AB There is provided a solid pharmaceutical compn. in a dosage form that is not enteric-coated, having active ingredients including a non-enteric coated proton pump inhibitor and at least one buffering agent. The proton pump inhibitor is omeprazole, lansoprazole, rabeprazole, esomeprazole, pantoprazole, pariprazole, and leminoprazole, or an enantiomer, isomer, deriv., free base, or salt thereof, in an amt. of approx. 5 mg to approx. 300 mg, and the buffering agent is in an amt. of approx. 0.1 mEq to approx. 2.5 mEq/mg proton pump inhibitor. The dosage form includes a suspension tablet, a chewable tablet, an effervescent powder, or an effervescent tablet. Also provided is a method for treating an acid-related gastrointestinal disorder in a subject by administering to the subject a solid pharmaceutical compn. Thus, a tablet formulation contained omeprazole 10, calcium lactate 175, calcium glycerophosphate 175, sodium bicarbonate 250, aspartame calcium (phenylalanine) 0.5, colloidal silicon dioxide 12, corn starch 15, Croscarmellose sodium 12, dextrose 10, peppermint 3, maltodextrin 3, mannitol 3, and pregelatinized starch 3 mg.

REFERENCE COUNT: 420 THERE ARE 420 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

technologies.

L21 ANSWER 8 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN  
ACCESSION NUMBER: 1999:407754 CAPLUS  
DOCUMENT NUMBER: 131:31323  
TITLE: Low-molecular nutrition mixture for treatment of  
malnutrition of various etiology  
INVENTOR(S): Veselkova, Anna; Petrzelka, Otta  
PATENT ASSIGNEE(S): Vyzkumny Ustav Antibiotik a Biotransformaci, Czech  
Rep.  
SOURCE: Czech Rep., 8 pp.  
CODEN: CZXXED  
DOCUMENT TYPE: Patent  
LANGUAGE: Czech  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CZ 283569	B6	19980513	CZ 1993-2791	19931216
SK 279874	B6	19990507	SK 1994-356	19940328

PRIORITY APPLN. INFO.: CZ 1993-2791 19931216  
AB A dietetic mixt. composed of mono and oligosaccharides, peptides prep'd. by controlled protein hydrolysis, glycerides with essential fatty acids and medium-chain fatty acids, vitamins, and trace minerals is described. The mixt. contains protein hydrolyzates (ovalbumin, soybean protein, casein, whey protein), glucose, sucrose, starch hydrolyzate, vegetable oil (safflower, soybean, sunflower) or oil with medium-chain fatty acids, NaCl, KCl, Ca glycerophosphate, MgO, trace elements (FeSO<sub>4</sub>, KI, Cu acetate, Mn acetate, ZnO, K<sub>2</sub>Cr<sub>2</sub>O<sub>7</sub>, ammonium molybdate), retinol acetate, ascorbic acid, thiamin dichloride, Na 5-riboflavinphosphate, pyridoxine chloride, nicotinamide, folic acid, Ca pantothenate, D-biotin, cyanocobalamin, inositol, ergocalciferol, tocopherol acetate, and phylloquinone. The mixt. can further contain flavoring agents. The mixt. can be used for nutritional support and treatment of malnutrition states, including conditions with altered gastrointestinal functions.

L21 ANSWER 10 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN  
ACCESSION NUMBER: 1994:14923 CAPLUS  
DOCUMENT NUMBER: 120:14923  
TITLE: Pharmaceutical compositions containing alginates and metal salts  
INVENTOR(S): Sentsova, Tatyana Nikolaevna; Yakubovich, Viktor Semenovich; Raskina, Ljudmila Pavlovna; Barabanov, Valery Alexandrovich; Ilchenko, Anatoly Afanasievich; Zhukhovitsky, Vladimir G.; Mikelson, Yanis Martynovich; Loginov, Anatoly Sergeevich; Melnichenko, Nadezhda T.; et al.  
PATENT ASSIGNEE(S): Vsesojuzny Nauchno-Issledovatel'sky Institut Meditsinskikh Polimerov, Russia  
SOURCE: PCT Int. Appl., 28 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: Russian  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9320826	A1	19931028	WO 1992-RU74	19920410
W: DE, GB, HU, JP, NL				
NL 9220019	A	19940405	NL 1992-20019	19920410
DE 4294862	T	19940609	DE 1992-4294862	19920410
JP 06508641	T2	19940929	JP 1992-518208	19920410
GB 2272375	A1	19940518	GB 1993-25480	19931210
GB 2272375	B2	19960214		

PRIORITY APPLN. INFO.: WO 1992-RU74 19920410

AB Pharmaceutical formulations of alginic acid or its pharmaceutically acceptable salts 5-91% and metal salts as the balance are described for prophylaxis and treatment of **gastrointestinal** disease, wound healing, and as hemostatic agents. Metals salts used include iron ammonium alum, iron **glycerophosphate**, iron lactate, reduced iron, base bismuth nitrate, potash alum, aluminum hydroxide, kaolin, barium sulfate, **calcium gluconate**, **calcium chloride** or **calcium carbonate**, optionally alone or in mixts. A 17 yr old with an ulcer 0.6 times 0.6 cm in the duodenal bulb was treated with aerosols of bismuth nitrate 0.2 g in six sessions. Mucous membrane biopsies and endoscopy showed improvement of the ulcer.

L3 ANSWER 2 OF 2 MEDLINE on STN  
ACCESSION NUMBER: 2002117832 MEDLINE  
DOCUMENT NUMBER: 21840079 PubMed ID: 11378102  
TITLE: The efficacy of calcium glycerophosphate in the prevention of food-related flares in **interstitial cystitis**.  
AUTHOR: Bologna R A; Gomelsky A; Lukban J C; Tu L M; Holzberg A S; Whitmore K E  
CORPORATE SOURCE: Pelvic Floor Institute, Graduate Hospital, Philadelphia, Pennsylvania, USA.  
SOURCE: UROLOGY, (2001 Jun) 57 (6 Suppl 1) 119-20.  
Journal code: 0366151. ISSN: 1527-9995.  
PUB. COUNTRY: United States  
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
LANGUAGE: English  
FILE SEGMENT: Priority Journals  
ENTRY MONTH: 200203  
ENTRY DATE: Entered STN: 20020220  
Last Updated on STN: 20020401  
Entered Medline: 20020326